JP2014505049A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505049A5
JP2014505049A5 JP2013547780A JP2013547780A JP2014505049A5 JP 2014505049 A5 JP2014505049 A5 JP 2014505049A5 JP 2013547780 A JP2013547780 A JP 2013547780A JP 2013547780 A JP2013547780 A JP 2013547780A JP 2014505049 A5 JP2014505049 A5 JP 2014505049A5
Authority
JP
Japan
Prior art keywords
ccr2
pharmaceutically acceptable
acceptable salt
angiotensin receptor
pathway inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013547780A
Other languages
English (en)
Japanese (ja)
Other versions
JP6087836B2 (ja
JP2014505049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2012/000014 external-priority patent/WO2012094703A1/en
Publication of JP2014505049A publication Critical patent/JP2014505049A/ja
Publication of JP2014505049A5 publication Critical patent/JP2014505049A5/ja
Application granted granted Critical
Publication of JP6087836B2 publication Critical patent/JP6087836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013547780A 2011-01-11 2012-01-11 併用療法 Active JP6087836B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2011900060 2011-01-11
AU2011900060A AU2011900060A0 (en) 2011-01-11 Combination Therapy
AU2011904279 2011-10-17
AU2011904279A AU2011904279A0 (en) 2011-10-17 Combination Therapy
PCT/AU2012/000014 WO2012094703A1 (en) 2011-01-11 2012-01-11 Combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016247754A Division JP2017078085A (ja) 2011-01-11 2016-12-21 併用療法

Publications (3)

Publication Number Publication Date
JP2014505049A JP2014505049A (ja) 2014-02-27
JP2014505049A5 true JP2014505049A5 (enExample) 2015-02-19
JP6087836B2 JP6087836B2 (ja) 2017-03-01

Family

ID=46506697

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013547780A Active JP6087836B2 (ja) 2011-01-11 2012-01-11 併用療法
JP2016247754A Pending JP2017078085A (ja) 2011-01-11 2016-12-21 併用療法
JP2018101282A Pending JP2018127498A (ja) 2011-01-11 2018-05-28 併用療法
JP2020084905A Pending JP2020122015A (ja) 2011-01-11 2020-05-14 併用療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016247754A Pending JP2017078085A (ja) 2011-01-11 2016-12-21 併用療法
JP2018101282A Pending JP2018127498A (ja) 2011-01-11 2018-05-28 併用療法
JP2020084905A Pending JP2020122015A (ja) 2011-01-11 2020-05-14 併用療法

Country Status (9)

Country Link
US (6) US9314450B2 (enExample)
EP (3) EP3586844A1 (enExample)
JP (4) JP6087836B2 (enExample)
CN (2) CN103476410B (enExample)
AU (1) AU2012206945B2 (enExample)
CA (1) CA2821985C (enExample)
IL (1) IL227414A (enExample)
WO (1) WO2012094703A1 (enExample)
ZA (1) ZA201305897B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547366A4 (en) 2010-03-18 2013-08-07 Univ Colorado State Res Found SUPPRESSOR CELL HEMMER OBTAINED FROM MYELOID CELLS
EP2726108B1 (en) 2011-06-29 2018-01-10 The Trustees of Columbia University in the City of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
WO2014075093A1 (en) * 2012-11-09 2014-05-15 The Trustees Of Columbia University In The City Of New York Inhibitors of central nervous system vasoactive inhibitory peptide receptor 2
JP2014193854A (ja) * 2013-02-28 2014-10-09 Santen Pharmaceut Co Ltd テトラヒドロピラニルアミノシクロペンチルカルボニルテトラヒドロピリドピリジン誘導体を有効成分として含有する後眼部疾患の予防または治療剤
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
WO2014134621A2 (en) * 2013-03-01 2014-09-04 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
CN103193771B (zh) * 2013-03-29 2015-08-05 中国人民解放军军事医学科学院生物工程研究所 链状酰胺类ccr5受体抑制剂的药物新用途
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
MX2017000580A (es) * 2014-07-17 2017-09-01 Santen Pharmaceutical Co Ltd Agente profilactico o terapeutico para enfermedades del segmento posterior del ojo.
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
EP3349751A4 (en) * 2015-09-16 2019-05-22 Tobira Therapeutics, Inc. CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
CN109153722A (zh) 2016-04-08 2019-01-04 X4 制药有限公司 用于治疗癌症的方法
EP3471726A4 (en) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP4134080B1 (en) 2016-11-23 2024-11-13 ChemoCentryx, Inc. Ccr2 inhibitors for use in treating renal diseases
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
CN108218789A (zh) * 2018-03-12 2018-06-29 钦州学院 碳13氘代甲基替米沙坦及其制备方法和用途
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP7501876B2 (ja) * 2019-04-17 2024-06-18 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CN114466653A (zh) * 2019-09-26 2022-05-10 戴麦里克斯生物科学有限公司 用于治疗疾病的方法和组合物
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
GB202006079D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
EP4146191A1 (en) * 2020-05-06 2023-03-15 Dimerix Bioscience Pty Ltd Treatment for acute respiratory distress syndrome
WO2021222971A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for virus induced acute respiratory distress syndrome
CN117042763A (zh) * 2021-03-23 2023-11-10 戴麦里克斯生物科学有限公司 炎性疾病的治疗
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd
TW202444344A (zh) * 2023-05-12 2024-11-16 澳大利亞商迪美力士生物科技有限公司 用於腎病之治療調配物
CN117054652B (zh) * 2023-08-04 2024-05-17 南京医科大学 一种用于辅助检测心肌肥厚的生物标志物及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JP2876058B2 (ja) 1986-08-18 1999-03-31 エミスフィア・テクノロジーズ・インコーポレイテッド 薬物送達システム
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
JPH059116A (ja) 1991-07-01 1993-01-19 Sanwa Kagaku Kenkyusho Co Ltd ３−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤
PT831911E (pt) * 1995-06-07 2002-09-30 Searle & Co Terapeutica de combinacao de espironolactona e antagonista da angiotensina ii para o tratamento de insuficiencia cardiaca congestiva
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
WO2000025134A1 (en) 1998-10-23 2000-05-04 Glaxo Group Limited Assays for ligands for nuclear receptors
DE60130538T2 (de) * 2000-02-03 2008-06-12 Millenium Pharmaceuticals, Inc., Cambridge Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
US6893827B1 (en) 2000-02-07 2005-05-17 Applera Corporation Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation
WO2003014110A1 (en) * 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Benzazepine derivative, process for producing the same, and use
DE10218785A1 (de) 2002-04-26 2003-11-13 Infineon Technologies Ag Halbleiterspeichereinrichtung und Betriebsverfahren für eine Halbleiterspeichereinrichtung
JP2004093527A (ja) 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
EP1481996A1 (en) 2003-05-30 2004-12-01 KRATON Polymers Research B.V. Process for making a coupled block copolymer composition
WO2005007822A2 (en) 2003-07-09 2005-01-27 Sentigen Biosciences, Inc. Method for assaying protein-protein interaction
US7488583B2 (en) 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
WO2005050182A1 (en) 2003-11-19 2005-06-02 Dimerix Biosciences Pty Ltd Resonance energy transfer assay system for multi-component detection
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
EP1787647B1 (en) * 2004-09-06 2012-06-20 Kowa Company, Ltd. Remedy for glomerular diseases
AR050631A1 (es) 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
US8058873B2 (en) 2006-11-10 2011-11-15 Koninklijke Philips Electronics N.V. Prevention quench in a magnetic resonance examination system
US8283127B2 (en) 2006-11-10 2012-10-09 Dimerix Bioscience Pty Ltd. Detection system and uses therefor
MX2009005252A (es) * 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
WO2008113095A1 (en) 2007-03-20 2008-09-25 Fibrotech Therapeutics Pty Ltd Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
KR20100087291A (ko) * 2007-09-25 2010-08-04 아보트 러보러터리즈 케모카인 수용체 길항제로서의 옥타하이드로펜탈렌 화합물
MX2010006089A (es) * 2007-12-04 2010-09-22 Schering Corp Metodos de tratamiento de enfermedad pulmonar obstructiva cronica.
US20110092463A1 (en) 2008-04-07 2011-04-21 Johan Raud Combination for use in the treatment of inflammatory disorders
EP2389178A4 (en) 2008-12-01 2012-06-06 Invasc Therapeutic Inc COMPOSITIONS CONTAINING INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND LIPOIC ACID COMPOUNDS, AND THEIR USE FOR THE TREATMENT OF RENIN-ANGIOTENSIN-ALDOSTERONE ASSOCIATED DISORDERS
US8537791B2 (en) 2009-01-20 2013-09-17 Lg Electronics Inc. Method and apparatus for channel access in contention-based communication system and station
US20120100130A1 (en) * 2009-03-27 2012-04-26 Dimerix Bioscience Pty Ltd. Novel Receptor Hetero-Dimers/-Oligomers

Similar Documents

Publication Publication Date Title
JP2014505049A5 (enExample)
Michel et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists
JP2018507244A5 (enExample)
JP6087836B2 (ja) 併用療法
DK3027183T3 (en) SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT
CN1312715A (zh) 缬沙坦和钙通道阻断剂的抗超敏组合
JP2020536919A5 (enExample)
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
JP2017520562A5 (enExample)
WO2017006254A1 (en) Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
Morganti et al. Aliskiren: the first direct renin inhibitor available for clinical use
JP2016538295A5 (enExample)
Riva et al. Which is the optimal antihypertensive combination in different diseases, a renin-angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
Lam Azilsartan: a newly approved angiotensin II receptor blocker
CN1249682A (zh) 用于治疗有症状的心力哀竭的血管紧张素ⅱ拮抗剂
CA2798573A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
JP2018521077A5 (enExample)
RU2016103099A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - i
JP2016505628A5 (enExample)
Parvanova et al. Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade
Destro et al. Olmesartan medoxomil: recent clinical and experimental acquisitions
Kim et al. Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
Hou et al. Optimal dose of angiotensin‐converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection
Vaněčková et al. Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade
Hashemzadeh et al. A novel design of combining the angiotensin converting enzyme (ACE) inhibitor captopril with the angiotensin receptor blocker (ARB) losartan using homo coupling via PEG diacid linker